Literature DB >> 28543950

Approach to Fingolimod-Induced Lymphopenia in Multiple Sclerosis Patients: Do We Have a Roadmap?

Jagannadha Avasarala1, Sandip Jain1, Enrique Urrea-Mendoza1.   

Abstract

Entities:  

Keywords:  disease management; drug information; immunopharmacology; neurology; pharmacovigilance

Mesh：

Substances：

Year:  2017        PMID： 28543950     DOI： 10.1002/jcph.945

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN： 0091-2700            Impact factor:   3.126


× No keyword cloud information.
  4 in total

Review 1.  Managing Risks with Immune Therapies in Multiple Sclerosis.

Authors:  Moritz Förster; Patrick Küry; Orhan Aktas; Clemens Warnke; Joachim Havla; Reinhard Hohlfeld; Jan Mares; Hans-Peter Hartung; David Kremer
Journal:  Drug Saf       Date:  2019-05       Impact factor: 5.606

Review 2.  Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis.

Authors:  H P Hartung; C Warnke; F Schweitzer; S Laurent; G R Fink; Michael H Barnett
Journal:  J Neurol       Date:  2020-02-08       Impact factor: 4.849

3.  Disease modifying therapies and infection risks in multiple sclerosis-a decision-making conundrum.

Authors:  Kok Pin Yong; Ho Jin Kim
Journal:  Ann Transl Med       Date:  2020-06

4.  Real World Lab Data: Patterns of Lymphocyte Counts in Fingolimod Treated Patients.

Authors:  Maxi Kaufmann; Rocco Haase; Undine Proschmann; Tjalf Ziemssen; Katja Akgün
Journal:  Front Immunol       Date:  2018-11-20       Impact factor: 7.561
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.